Bicalutamide was discovered by Tucker and colleagues at Imperial Chemical Industries (ICI) in the 1980s and was selected for development from a group of over 2,000 synthesized compounds. It was first patented in 1982 and was first reported in the scientific literature in June 1987.Bicalutamide was first studied in a phase I clinical trial in 1987 and the results of the first phase II clinical trial in prostate cancer were published in 1990. The pharmaceutical division of ICI was split out into an independent company called Zeneca in 1993, and in April and May 1995, Zeneca (now AstraZeneca, after merging with Astra AB in 1999) began pre-approval marketing of bicalutamide for the treatment of prostate cancer in the U.S.. It was first launched in the U.K. in May 1995, and was subsequently approved by the U.S. FDA on 4 October 1995, for the treatment of prostate cancer at a dosage of 50 mg/day in combination with a GnRH analogue.Following its introduction for use in combination with a GnRH analogue, bicalutamide was developed as a monotherapy at a dosage of 150 mg/day for the treatment of prostate cancer, and was approved for this indication in Europe, Canada, and a number of other countries in the late 1990s and early 2000s. This application of bicalutamide was also under review by the FDA in the U.S. in 2002, but ultimately was not approved in this country. In Japan, bicalutamide is licensed at a dosage of 80 mg/day alone or in combination with a GnRH analogue for prostate cancer.
Lipoatrophia semicircularis is a medical condition in humans, commonly known as ribbed thighs. It consists of a semicircular zone of atrophy of the subcutaneous fatty tissue located mostly on the front of the thighs. Skin and underlying muscles remains intact. Semicircular lipoatrophy mainly affects office workers. The ribs in the thighs are typically between 2 and 4 cm high and are typically located at about 72 cm above the ground, which is the standard height of office furniture. Cause
It is not yet clear what exactly causes semicircular lipoatrophy. Some hypotheses are that it is caused by localized pressure or by electromagnetic fields. Diagnosis
Treatment
See also
Lipodystrophy
List of cutaneous conditions

References


== External links ==